The European Commission has rubberstamped a recommendation for approval for the Kixelle (insulin aspart) biosimilar to Novo Nordisk’s NovoRapid, handing a significant marketing authorization to the newly-formed Viatris and its development partner Biocon.
“While management has not indicated specific launch timing of the approved Kixelle, we believe it will be commercialized during the first half of 2021 – Biocon previously indicated that it expects to launch during its